Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II/III trial of PRV-002 to treat Traumatic-brain-injuries (concussion)

Next Previous
X
Search
Trial Profile

A phase II/III trial of PRV-002 to treat Traumatic-brain-injuries (concussion)

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 13 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PRV-002 (Primary)
  • Indications Traumatic brain injuries
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 08 Aug 2024 According to a Oragenics Inc media release, the company has completed FDA-Required cardiotoxicity testing, prior to conducting trial in USA.
    • 19 Dec 2022 According to an Odyssey Pharmaceuticals Inc media release, the company is seeking sites in Australia to start the Phase II trial.
    • 12 Jul 2022 According to a Odyssey Pharmaceuticals Inc media release, phase II trial sites are being identified and study design is being created with the site's medical leadership and the Odyssey Medical Advisors.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top